Menu
MorphoSys US

Our mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases.

Taking Big Steps

Visit our Online Magazine

MorphoSys' mission

MorphoSys mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

Latest
news

11/11/2020
MorphoSys Reports Nine Months and Third Quarter 2020 Results
Read Media Release
11/11/2020
MorphoSys and Cherry Biolabs Announce licensing of Hemibody Technology
Read Media Release
11/11/2020
Xencor, MorphoSys and Incyte Enter into Global Development Collaboration...
Read Media Release
04/11/2020
MorphoSys to Present Data on Tafasitamab at the ASH Virtual Annual Meeting...
Read Media Release
04/11/2020
Invitation to MorphoSys' Third Quarter and First 9-Month 2020 Results...
Read Media Release
27/10/2020
Ad hoc: MorphoSys AG Raises its Financial Guidance for the Full Year 2020
Read Media Release
19/10/2020
MorphoSys' Licensee Janssen Receives CHMP Positive Opinion for...
Read Media Release
13/10/2020
MorphoSys AG Successfully Places EUR 325 Million Convertible Bonds
Read Media Release
13/10/2020
Ad hoc: MorphoSys AG Launches an Offering of approx. EUR 325 Million...
Read Media Release
30/09/2020
MorphoSys Announces Departure of Jens Holstein, CFO, by Year End 2020
Read Media Release

November 17, 2020
Webcast
Stifel 2020 Virtual HC Conference

Full details

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

Do you wish to proceed?

Yes No